Cancer

TOPIC

Cancer

Cancer

Tumors originate from the alteration of cells that multiply and spread escaping the mechanisms that maintain the balance of the different tissues. There are numerous types of tumors that can affect virtually any organ and are generally classified as benign or malignant depending on its ability to invade surrounding tissues and more distant organs. The term neoplasms include solid organ tumors and those of blood cells such as lymphomas and leukemias. Some tumors are exclusive or more frequent in the male or female gender and differences in genders can also be observed in the response to therapies.

Despite the great successes obtained in the last decades with prevention, early diagnostics and therapy measures, malignant tumors continue to be among the leading causes of death and deterioration of life quality; and also due to longer average life spans, in many cases, cancer incidence increases with age. For some neoplasms, mortality has decreased markedly; for others, despite the great commitment of research, the need remains to find new, more effective and specific therapies.

Cancer therapy is essentially based on surgery, especially in localized forms, radiotherapy and drugs. By identifying molecular alterations (tumor genetics) or targets that are present exclusively, or prevalently, on cancer cells, drugs have been developed in recent years aimed at selectively targeting cancer cells. Prevention is fundamental, and by studying the epidemiology of tumors it is possible to identify environmental or lifestyle-related risk factors that can be corrected to reduce the risk of developing cancer.

The Istituto Superiore di Sanità (ISS, the National Institute of Health in Italy) carries out research in the field of oncology, hematology and genetic diseases, and with a translational orientation.



Back RARECAREnet - Information Network for Rare Cancer

RARECAREnet è un progetto della Comunità Europea coordinato dall'Istituto dei Tumori di Milano, che negli ultimi anni ha aggiornato le stime dell’impatto dei tumori rari in Europa, delle loro tendenze temporali nell'incidenza e della sopravvivenza, grazie ai dati provenienti da 94 registri tumori di popolazione per un totale di oltre 2 milioni di diagnosi di circa 200 tipi di tumore maligno raro. 

Basandosi sull'esperienza del precedente progetto RARECARE e, in collaborazione con RCE- Rare Cancer Europe e molte altre realtà,  RARECARENet mira a costruire una un network per fornire alla comunità informazioni complete e aggiornate su tumori rari (oncologi, medici in generale, ricercatori, autorità sanitarie, pazienti e le loro famiglie).

Nel 2011, all'interno del primo progetto RARECARE, poi confluito in RARECAREnet,  è stato individuato il criterio che identifica un tumore raro, ovvero un'incidenza che non superi la soglia di 6 casi su 100.000 nella popolazione europea.
Tale criterio, ormai accettato da tutti a livello internazionale,ha premesso ai ricercatori di individuare  198 tumori rari (la lista è consultabile online).


Dipartimenti/Centri/Servizi

National center for rare diseases

Topics

Rare cancers Genetics and rare tumors